Literature DB >> 6581147

Prostaglandin production by human trabecular cells: in vitro inhibition by dexamethasone.

R N Weinreb, M D Mitchell, J R Polansky.   

Abstract

In addition to the well-known ability of prostaglandins (PGs) to raise intraocular pressure (IOP), it recently has been reported that moderate and low doses of PGE2 and PGF2 alpha significantly reduce IOP in a variety of experimental animals. These studies suggested to us that PGs might serve as endogenous regulators of outflow facility in the meshwork if these autacoids were produced and secreted by human trabecular cells. To examine this possibility, media from well-defined trabecular cell material were assayed using specific radioimmunoassays. Morphologically differentiated human trabecular cells produced high levels of PGE2, and somewhat lower levels of PGF2 alpha and 6KF1 alpha in the presence and absence of serum. In a typical experiment, the following PG levels were detected in the cell culture media after 24 hours: PGE2; 225; PGF2 alpha, 33.5; 6KF1 alpha, 12.7 ng/ml with the presence of 10% fetal calf serum; and PGE2, 30.0; PGF2 alpha, 4.8; 6KF1 alpha, 3.6 ng/ml in serum-free media. Since glucocorticoids are known to inhibit PG pathways in other tissues, this effect was examined in the cultured trabecular cells. Moderate concentrations of dexamethasone (DEX) produced a marked inhibition in the levels of all three PGs. For PGE2 production, 10(-8) M DEX inhibited approximately 75%, and 10(-7) M DEX inhibited approximately 90%. More detailed dose-response studies revealed that the I50 for inhibition of PG production by dexamethasone was less than 10 nM, thus indicating that the steroid effect probably involved high affinity glucocorticoid receptors.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6581147

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  12 in total

1.  The role of prostaglandins in the para-aminoclonidine-induced reduction of intraocular pressure.

Authors:  R F Wang; C B Camras; S M Podos; K W Lee; K C Bhuyan; D K Bhuyan
Journal:  Trans Am Ophthalmol Soc       Date:  1989

Review 2.  Corticosteroids and glaucoma risk.

Authors:  R C Tripathi; S K Parapuram; B J Tripathi; Y Zhong; K V Chalam
Journal:  Drugs Aging       Date:  1999-12       Impact factor: 3.923

3.  Histoautoradiographic and electron microscopic studies on short-term explant cultures of the glaucomatous trabecular meshwork.

Authors:  J W Rohen; A Ogilvie; E Lütjen-Drecoll
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1985       Impact factor: 3.117

4.  Intracellular calcium response to hydraulic pressure in human trabecular cells.

Authors:  T Matsuo; N Matsuo
Journal:  Br J Ophthalmol       Date:  1996-06       Impact factor: 4.638

5.  The short-term effects of intranasal steroids on intraocular pressure in pediatric population.

Authors:  Taylan Ozturk; Ceren Durmaz Engin; Seher Koksaldi; Gul Arikan
Journal:  Int Ophthalmol       Date:  2022-07-12       Impact factor: 2.029

6.  Despite a massive increase in cortisol secretion in women during parturition, there is an equally massive increase in prostaglandin synthesis. A paradox?

Authors:  M L Casey; P C MacDonald; M D Mitchell
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

Review 7.  Biological properties of trabecular meshwork cells.

Authors:  Joshua Z Gasiorowski; Paul Russell
Journal:  Exp Eye Res       Date:  2008-08-26       Impact factor: 3.467

8.  Endogenous Bioactive Lipids and the Regulation of Conventional Outflow Facility.

Authors:  Zhou Wan; David F Woodward; W Daniel Stamer
Journal:  Expert Rev Ophthalmol       Date:  2008

9.  Localisation of prostaglandin F2 alpha and E2 binding sites in the human eye.

Authors:  T Matsuo; M S Cynader
Journal:  Br J Ophthalmol       Date:  1992-04       Impact factor: 4.638

Review 10.  Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction.

Authors:  Carol B Toris; B'Ann T Gabelt; Paul L Kaufman
Journal:  Surv Ophthalmol       Date:  2008-11       Impact factor: 6.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.